• 
• See all for Dividend.com
• View Print Version

• Best Dividend Stocks
• High-Yield Dividend Stocks
• Ex-Dividend Calendar

• LLY 100% Rate It

Pharmaceuticals maker Eli Lilly & Co. ( LLY ) on Monday received a big downgrade from anlaysts at Jefferies & Co.

The firm slashed its rating on LLY from "Hold" to "Underperform" with a $35 price target, suggesting a big 21% downside to the stock's Friday closing price of $44.37.

Jefferies noted it expects Lilly's new Alzheimer's treatment, called solanezumab, to fail its pivotal studies. The company is expected to release data from recently-completed late-stage trials in August.

The analyst commented, "We expect that solanezumab will outright fail its pivotal studies in Alzheimer's disease…with only a 25 percent chance of being effective in a niche population."

Eli Lilly shares were mostly flat in premarket trading Monday.

The Bottom Line
Shares of Eli Lilly ( LLY ) have a 4.42% dividend yield, based on Friday's closing stock price of $44.37. The stock has technical support in the $40 price area. If the shares can firm up, we see overhead resistance around the $45-$47 price levels.

Eli Lilly & Co. ( LLY ) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.4 out of 5 stars.

Be sure to visit our complete recommended list of the Best Dividend Stocks , as well as a detailed explanation of our ratings system here .

Related Stocks Articles

• 
  Company News for May 23, 2013 - Corporate Summary
  5/23/2013 10:31 AM
• 
  Wyndham Closes Credit Facility - Analyst Blog
  5/23/2013 10:30 AM
• 
  Is the Market Over-Reacting? - Ahead of Wall Street
  5/23/2013 10:30 AM